Adaptimmune Therapeutics plc (ADAP) Financials

ADAP Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 282.6 million 243.1 million
2023-09-30 296.6 million 208.5 million
2023-06-30 343.0 million 216.3 million
2023-03-31 288.1 million 204.2 million

ADAP Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -15.5 million 3.1 million
2023-09-30 -45.4 million 3.2 million
2023-06-30 -45.0 million 3.8 million
2023-03-31 -39.8 million 1.7 million

ADAP Net Income

No data available :(

ADAP Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 146.9 million - 25.2 million
2023-09-30 161.7 million - 25.6 million
2023-06-30 204.7 million - 26.3 million
2023-03-31 165.6 million - 22.8 million

ADAP Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 227.1 million
2023-09-30 135.8 million
2023-06-30 184.7 million
2023-03-31 166.7 million

ADAP Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 828016 37.2 million 16.9 million 2.7 million
2023-09-30 289000 37.8 million 16.2 million -
2023-06-30 1.2 million 30.0 million 20.1 million -
2023-03-31 2.5 million 25.5 million 20.4 million -

ADAP Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 233009 2.9 million
2023-09-30 7.3 million 2.9 million
2023-06-30 5.1 million 2.2 million
2023-03-31 47.6 million 1.9 million

ADAP

Price: $1.18

52 week price:
0.42
2.05

Earnings Per Share: -0.54 USD

P/E Ratio: -2.30

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 237100

Ebitda: 858000

Market Capitalization: 318.4 million

Links: